Artem Poltoratskiy
A5084070841- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- Nanoparticle-Based Drug Delivery
- Catalytic Processes in Materials Science
- CAR-T cell therapy research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Pneumonia and Respiratory Infections
- Cancer Risks and Factors
- Toxin Mechanisms and Immunotoxins
- Gastric Cancer Management and Outcomes
- Cancer-related cognitive impairment studies
- Metal-Organic Frameworks: Synthesis and Applications
Institute of Oncology NN Petrov
2016-2025
Saint Petersburg State Pediatric Medical University
2014
<h3>Importance</h3> There are no specifically approved targeted therapies for the most common genomically defined subset of non–small cell lung cancer (NSCLC),<i>KRAS</i>-mutant cancer. <h3>Objective</h3> To compare efficacy mitogen-activated protein kinase (MEK) inhibitor selumetinib + docetaxel with alone as a second-line therapy advanced<i>KRAS</i>-mutant NSCLC. <h3>Design, Setting, and Participants</h3> Multinational, randomized clinical trial conducted at 202 sites across 25 countries...
In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab tremelimumab numerically OS EP, but did not reach statistical significance. Here we report updated censored patients after median follow-up of >3 years.805 treatment-naïve ES-SCLC were randomized 1 : to EP. The two primary endpoints for and EP.As...
In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of outcomes by programmed death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB).
The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety of first-line osimertinib with platinum-pemetrexed chemotherapy versus monotherapy in epidermal growth factor receptor mutation-positive (EGFRm) advanced/metastatic non-small-cell lung cancer (NSCLC). run-in, reported here, assessed the tolerability prior to randomized evaluation.Patients (≥18 years; Japan: ≥20 years) EGFRm locally NSCLC received oral 80 mg once daily (QD), either intravenous (IV) cisplatin 75 mg/m2...
The efficacy and safety of axitinib, a potent selective second-generation inhibitor vascular endothelial growth factor receptors 1, 2, 3 in combination with pemetrexed cisplatin was evaluated patients advanced non-squamous non–small-cell lung cancer (NSCLC). Overall, 170 were randomly assigned to receive axitinib at starting dose 5-mg twice daily continuously plus 500 mg/m2 75 on day 1 up six 21-day cycles (arm I); days 2 through 19 each cycle pemetrexed/cisplatin II); or alone III). primary...
9002 Background: CASPIAN is an open-label, Phase 3 study of durvalumab (D) ± tremelimumab (T) + etoposide and either cisplatin or carboplatin (EP) for pts with 1L ES-SCLC. At the planned interim analysis (data cutoff Mar 11, 2019; 63% maturity), D EP demonstrated a statistically significant improvement in OS compared alone (HR 0.73 [95% CI 0.59–0.91]; p=0.0047). Here we present updated vs first results T EP. Methods: Treatment-naïve ES-SCLC (WHO PS 0/1) were randomized 1:1:1 to 1500 mg q3w,...
In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone patients extensive-stage small-cell lung cancer (ES-SCLC) at interim analysis. Here we report patient-reported outcomes (PROs).Treatment-naïve ES-SCLC received 4 cycles of every 3 weeks followed by maintenance until progression, up to 6 weeks. PROs, assessed European Organisation for Research...
Background CV8102, a toll-like receptor 7/8 and RIG I agonist, has demonstrated antitumor immune responses in preclinical studies. We investigated intratumoral (IT) administration of CV8102 patients with anti-programmed cell death protein-1 (PD-1) therapy-naïve or anti-PD-1 therapy-refractory cutaneous melanoma (cMEL) advanced squamous carcinoma, head neck carcinoma adenoid cystic carcinoma. Methods This open-label, cohort-based, phase dose escalation study aimed to establish the maximum...
Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often exclude treated in routine clinical practice. We report interim results from Phase 3b, open-label, multicenter, single-arm, exploratory trial, which was investigated real-world setting.Patients EGFRm + tyrosine kinase inhibitor (TKI)-naïve NSCLC received 40 mg...
Afatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis three phase IIIb studies afatinib in EGFR tyrosine kinase inhibitor (TKI)-naïve patients.EGFR-TKI-naïve EGFRm+ NSCLC received 40 mg/day. Dose reductions were permitted adverse events (AEs). Efficacy endpoints included progression-free survival (PFS), time to symptomatic progression...
In FLAURA2 (NCT04035486) 1L osi with addition of platinum-pemetrexed chemotherapy (osi+CTx) showed significant PFS benefit vs alone (HR 0.62 [95% CI 0.49, 0.79] p<0.0001, per investigator) in EGFRm advanced NSCLC. Higher ≥Grade 3 (G3) AE rates were seen osi+CTx osi, driven by well-recognised CTx-related AEs. We report additional safety analyses specific AEs interest from FLAURA2. Eligible pts (≥18 years NSCLC, no prior tx for NSCLC; stable CNS metastases allowed) randomised 1:1 to (osi once...
<div>AbstractPurpose:<p>In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of outcomes by programmed death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB).</p>Experimental Design:<p>Patients were randomized (1:1:1) to (1,500 mg) EP, tremelimumab (75 or alone. Treatment effects PD-L1...
<p>Kaplan-Meier analysis of OS for (A) the tTMB <10 mut/Mb subgroup and (B) ≥10 subgroup.</p>
<p>Kaplan-Meier analysis of OS in the ITT population and PD-L1 BEP.</p>
<p>Subgroup analysis of confirmed ORR by PD-L1 TC and IC expression for (A) durvalumab plus tremelimumab EP versus (B) EP. In each panel, the shaded band shows confidence interval ITT population; circle sizes are proportional to number responses. Groups not plotted when there ≤5 responses across both arms.</p>
<p>Sample flow for biomarker analysis.</p>